Tvardi Therapeutics (NASDAQ:TVRD) Now Covered by Chardan Capital

Equities researchers at Chardan Capital began coverage on shares of Tvardi Therapeutics (NASDAQ:TVRD) in a report issued on Tuesday, MarketBeat reports. The firm set a “buy” rating on the stock.

TVRD has been the topic of a number of other reports. Lucid Cap Mkts raised shares of Tvardi Therapeutics to a “strong-buy” rating in a report on Tuesday, September 8th. Wall Street Zen cut shares of Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, October 12th. UBS Group raised shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 price target on the stock in a report on Wednesday, July 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, October 2nd. Finally, BTIG Research lowered their price target on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $9.40.

Tvardi Therapeutics Stock Up 7.6%

Shares of TVRD stock traded up $0.07 on Tuesday, reaching $1.04. The stock had a trading volume of 50,291 shares, compared to its average volume of 794,856. The firm’s 50-day moving average is $1.55 and its two-hundred day moving average is $2.46. The firm has a market capitalization of $13.93 million, a price-to-earnings ratio of -0.37 and a beta of 0.38. Tvardi Therapeutics has a 12 month low of $0.93 and a 12 month high of $6.13.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its earnings results on Friday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). On average, sell-side analysts forecast that Tvardi Therapeutics will post -2.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in TVRD. GSA Capital Partners LLP acquired a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $34,000. Susquehanna International Group LLP acquired a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $63,000. Finally, BlackRock Inc. acquired a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $181,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

About Tvardi Therapeutics

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s research is centered on inhibiting STAT3, a protein involved in tumor growth, immune evasion, inflammation and resistance to existing treatments.

Tvardi’s lead investigational product is TTI-101, an oral, small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. The company is investigating the therapy both as a standalone treatment and in combination with other anticancer therapies, with the goal of addressing cancers in which STAT3 activity contributes to disease progression.

Tvardi Therapeutics is headquartered in Houston, Texas, and its development programs are focused on advancing targeted medicines through clinical testing.